Evidence map›Paper›PMID 40529098›Full record

ArticleACS medicinal chemistry letters2025

Synthetic Lethality as Emerging Treatment for Cancer: An Example by Using the Werner Syndrome Helicase (WRN) Inhibitors.

Ahmed F Abdel-Magid

Abstract readEditorial
In one paragraph

Article in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Ahmed F Abdel-MagidIndependent Consultant, 1383 Jasper Drive, Ambler, Pennsylvania 19002, United States.ORCID https://orcid.org/0000-0001-7438-1414

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The invention in this patent application relates to chemical compounds represented herein generally by Formula 1a. These compounds are inhibitors of the Werner Syndrome ATP-dependent helicase (WRN) enzyme activity. The compounds of the invention may particularly be useful in treating cancers characterized by microsatellite instability (MSI) and/or defective DNA mismatch repair (dMMR) system.

Identifiers

PMID40529098
PMCPMC12169599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.